Brought to you by 
Infinity signs on AbbVie to help with late-stage cancer candidate duvelisib; deal ends
08 Jul 2016
Executive Summary
Infinity Pharmaceuticals Inc. partnered its blood cancer candidate duvelisib (IPI145) with AbbVie Inc. Duvelisib, an oral phosphoinositide-3-kinase (PI3K)-delta/PI3K-gamma inhibitor, is currently in Phase II for indolent non-Hodgkin lymphoma (iNHL) and Phase III for chronic lymphocytic leukemia (CLL). The compound is also in Phase I for patients with advanced blood cancers.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com